Safety Seen in AMT-130 Gene Therapy Trial, Six More Patients to Enroll
No significant safety concerns were found in the first four patients participating in a Phase 1/2 trial assessing the safety and efficacy of uniQure’s AMT-130, an experimental gene therapy for Huntington’s disease. This…
